Entheon Biomedical Corp. ENTBF

ENTBF Company Overview

Entheon Biomedical Corp. was a clinical-stage biotechnology company focused on developing psychedelic-derived therapeutics, primarily for the treatment of substance use disorders and addiction. The company operated within the biotechnology and mental health therapeutics industries, with a strategic emphasis on regulated pharmaceutical development rather than consumer or wellness applications. Its core research centered on dimethyltryptamine (DMT)–based compounds administered in controlled clinical settings.

The company’s primary value proposition was its attempt to position short-acting psychedelic compounds as potentially scalable treatments for addiction, differentiating itself from longer-duration psychedelic therapies. Entheon was incorporated in Canada and became publicly traded in 2020. Based on publicly available corporate disclosures and market reporting, Entheon experienced financial and operational challenges and significantly reduced or ceased active operations by 2023. Certain aspects of its later-stage corporate status are not consistently reported across sources; data inconclusive based on available public sources.